Patent ID: 9572863
Date: 2017-02-21
CPC Classifications: A61K,A61P

Claim:
1. A method of treating or ameliorating a lung disorder that is related to the immune system, comprising administering to a subject in need thereof a human tear lipocalin mutein or a fusion protein, conjugate or composition thereof that is capable of inhibiting IL-4 and/or IL-13 from binding to their respective receptors, wherein said lipocalin mutein is capable of exhibiting in vivo therapeutic activity in the subject, wherein said lipocalin mutein has at least 75% sequence identity to the amino acid sequence of mature human tear lipocalin (SEQ ID NO: 1), wherein said lipocalin mutein has the following amino acid residues at amino acid positions corresponding to numbering of amino acids positions of mature human tear lipocalin (SEQ ID NO: 1): Ser at amino acid position 26, Arg at amino acid position 27, Cys at amino acid position 28, Arg at amino acid position 30, Ala at amino acid position 31, Val at amino acid position 32, Tyr at amino acid position 33, Asn at amino acid position 34, Phe at amino acid position 53, Ala at amino acid position 55, Gln at amino acid position 56, Arg at amino acid position 57, Lys at amino acid position 58, Trp at amino acid position 61, Lys at amino acid position 63, Tyr at amino acid position 64, Leu at amino acid position 66, Ser at amino acid position 80, Arg at amino acid position 83, Leu at amino acid position 104, Cys at amino acid position 105, Pro at amino acid position 106, and Gln at amino acid position 108.